Register for real-time alerts, custom portfolio, and market movers

Get Started

ABBV

AbbVie (ABBV)

AbbVie Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next >>

Date	Time	Source	Headline	Symbol	Company
04/05/2023	4:34PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ABBV	AbbVie Inc
04/04/2023	8:00AM	PR Newswire (US)	AbbVie to Host First-Quarter 2023 Earnings Conference Call	NYSE:ABBV	AbbVie Inc
04/03/2023	8:00AM	PR Newswire (US)	CoolSculpting® Elite Announces First Ever CoolMonth	NYSE:ABBV	AbbVie Inc
03/29/2023	9:00AM	PR Newswire (US)	Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023	NYSE:ABBV	AbbVie Inc
03/28/2023	4:40PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:ABBV	AbbVie Inc
03/28/2023	6:02AM	Edgar (US Regulatory)	Notice of Exempt Solicitation. Definitive Material. (px14a6g)	NYSE:ABBV	AbbVie Inc
03/23/2023	9:26AM	Dow Jones News	AbbVie's Skyrizi Hits Goals in Ulcerative Colitis Study	NYSE:ABBV	AbbVie Inc
03/23/2023	9:00AM	PR Newswire (US)	AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus	NYSE:ABBV	AbbVie Inc
03/23/2023	8:30AM	PR Newswire (US)	Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis	NYSE:ABBV	AbbVie Inc
03/22/2023	9:44AM	Dow Jones News	FDA Rejects AbbVie Parkinson's Treatment; Seeks More Data	NYSE:ABBV	AbbVie Inc
03/22/2023	8:45AM	PR Newswire (US)	AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application	NYSE:ABBV	AbbVie Inc
03/21/2023	5:23PM	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NYSE:ABBV	AbbVie Inc
03/20/2023	5:01PM	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NYSE:ABBV	AbbVie Inc
03/18/2023	10:03AM	PR Newswire (US)	AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy	NYSE:ABBV	AbbVie Inc
03/15/2023	5:01PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
03/15/2023	8:03AM	PR Newswire (US)	AbbVie Partners with Award-Winning Redglass Pictures on New Film Shedding Light on the Hidden Struggles of Those Living with Eczema	NYSE:ABBV	AbbVie Inc
03/13/2023	8:03AM	PR Newswire (US)	AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting	NYSE:ABBV	AbbVie Inc
03/08/2023	8:45AM	PR Newswire (US)	BOTOX® Cosmetic (onabotulinumtoxinA) Partners with IFundWomen to Help Close the Confidence Gap for Women Entrepreneurs	NYSE:ABBV	AbbVie Inc
03/08/2023	8:00AM	PR Newswire (US)	AbbVie to Present at the Barclays Global Healthcare Conference	NYSE:ABBV	AbbVie Inc
03/06/2023	5:02PM	Edgar (US Regulatory)	Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)	NYSE:ABBV	AbbVie Inc
03/02/2023	5:08PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
03/02/2023	5:08PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
03/02/2023	5:05PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
03/02/2023	5:04PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
03/02/2023	5:03PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
03/02/2023	4:31PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
03/02/2023	4:31PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:ABBV	AbbVie Inc
02/28/2023	8:51AM	PR Newswire (US)	AbbVie to Present at the Cowen 43rd Annual Health Care Conference	NYSE:ABBV	AbbVie Inc
02/27/2023	6:00AM	PR Newswire (US)	AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO)	NYSE:ABBV	AbbVie Inc
02/27/2023	2:00AM	PR Newswire (US)	AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Crohn's Disease	NYSE:ABBV	AbbVie Inc

Showing the most relevant articles for your search:NYSE:ABBV

<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next >>

Marketing Worldwide (PK)

Bell Buckle (PK)

Seafarer Exploration (PK)

Canopus Biopharma (PK)

NioCorp Developments

Brookmount Explorations (PK)

Therapeutic Solutions (PK)

Seven Arts Entertainment (PK)

Virexit Technologies (PK)

Fannie Mae (QB)

Decentral Life (PK)

Ubiquitech Software (PK)

Kraig Biocraft Laborator... (QB)

Delayed Upgrade Clock